Skip to content
Open access

Neoadjuvant immunochemotherapy vs. neoadjuvant chemotherapy or concurrent chemoradiotherapy in unresectable locally advanced esophageal squamous cell carcinoma.

Nov 2026 · Digestive and Liver Disease · 0 citations · 22 references
Medicine

TL;DR

NICT was associated with improved survival compared with either NCT or CCRT, and these findings are hypothesis-generating and require prospective validation.

Abstract

Purpose

To compare the efficacy between neoadjuvant immunochemotherapy (NICT), neoadjuvant chemotherapy (NCT), and concurrent chemoradiotherapy (CCRT) in patients with unresectable locally advanced esophageal squamous cell carcinoma.

Materials And Methods

We retrospectively analyzed patients with stage II-IVA disease treated between January 2013 and May 2024. Patients were categorized into the CCRT, NCT, and NICT groups. Survival outcomes were compared using Kaplan-Meier analysis and Cox proportional hazards models.

Results

A total of 347 patients were included: 214 (61.7%) in the CCRT group, 42 (12.1%) in the NCT group, and 91 (26.2%) in the NICT group. Compared with CCRT, NICT was associated with improved disease-free survival (HR = 0.57, 95% CI: 0.41-0.80, P = 0.001) and overall survival (HR = 0.48, 95% CI: 0.32-0.72, P < 0.001). Compared with NCT, NICT was associated with improved disease-free survival (HR = 0.51, 95% CI: 0.32-0.79, P = 0.003) and overall survival (HR = 0.40, 95% CI: 0.24-0.65, P < 0.001). The survival benefit associated with NICT was observed in patients who received >3 cycles (HR = 0.31, 95% CI: 0.15-0.63, P = 0.001).

Conclusion

NICT was associated with improved survival compared with either NCT or CCRT. These findings are hypothesis-generating and require prospective validation.

Read PDF

Similar papers

Oct 2026

Superior Prognosis of Neoadjuvant Immunochemotherapy over Neoadjuvant Chemoradiotherapy in Esophageal Squamous Cell Carcinoma Patients with pCR.

BACKGROUND Neoadjuvant chemoradiotherapy (NCRT) is the standard regimen for locally advanced esophageal squamous cell carcinoma (ESCC), while neoadjuvant immunochemotherapy (NICT) has emerged as a promising alternative. Achieving pathological complete response (pCR) after neoadjuvant therapy is associated with favorabl...

Pin-Hao Fang, Xin Xiao, Cheng-Yi Mao et al. · 0 citations
Open access Oct 2026

Efficacy comparison of neoadjuvant chemotherapy, chemoradiotherapy, and chemoimmunotherapy in resectable esophageal squamous cell carcinoma: short- and long-term outcomes from a propensity score-matched analysis

Introduction This study consecutively enrolled patients with resectable locally advanced esophageal squamous cell carcinoma (ESCC) treated at Fujian Medical University Union Hospital and Gaozhou People's Hospital between January 1, 2,019, and January 1, 2022. Methods All patients received neoadjuvant therapy followed b...

Hai Zhang, Yun Liang, Chao-Lin Li et al. · 0 citations
Sep 2026

Real-World Analysis of Neoadjuvant Immunochemotherapy Followed by Surgery in Esophageal Cancer with Baseline Supraclavicular Lymph Node Involvement.

Although PORT did not significantly improve survival in the overall cSCLN+ population, a trend toward improved OS was observed in the cSCLN+pSCLN+ subgroup, suggesting PORT may be considered as a potential strategy to improve survival outcomes.

Yi-Meng Yu, Lin Lin, Ya Zeng et al. · 0 citations
Open access Nov 2026

Upfront surgery versus neoadjuvant chemoimmunotherapy versus neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma in elderly patients: a multicenter cohort study

The optimal treatment strategy for elderly patients (aged ≥65 years) with operable locally advanced esophageal squamous cell carcinoma (ESCC) remains controversial. This study aimed to compare the survival outcomes of upfront surgery (US), neoadjuvant chemoimmunotherapy (nCIT), and neoadjuvant chemoradiotherapy (nC...

Z. Hou, Yi-Xiang Zhu, M. Lan et al. · 0 citations
Open access Nov 2026

Real-world comparative effectiveness of neoadjuvant chemoimmunotherapy versus chemotherapy for locally advanced esophageal squamous cell carcinoma: a retrospective cohort study

Neoadjuvant chemoimmunotherapy (NCIT) has shown higher pathologic response rates than neoadjuvant chemotherapy (NCT) in patients with locally advanced esophageal squamous cell carcinoma (LA-ESCC). Recent studies have reported comparative survival outcomes, but evidence from extended follow-up remains limited....

Y. Ao, Chang-Sen Leng, Kong-Jia Luo et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.